1 **Noninvasive diagnosis of secondary infections in COVID-19 by sequencing of plasma microbial cell-**

2 **free DNA.**

- 3
- 4 Grace Lisius¹, Radha Duttagupta², Asim A. Ahmed², Matthew Hensley³, Nameer Al-Yousif⁴, Michael Lu¹,
- 5 Milliam Bain^{3,5,6}, Faraaz Shah^{3,5}, Caitlin Schaefer^{3,5}, Shulin Qin^{3,7}, Xiaohong Wang³, Yingze Zhang^{3,5}, Kevin J.
- 6 Mitchell⁸, Ellen K. Hughes⁸, Jana L. Jacobs⁹, Asma Naqvi⁹, Ghady Haidar⁹, John W. Mellors⁹,
- 7 Barbara Methé^{3,7}, Bryan J. McVerry^{3,5,7}, Alison Morris^{3,7}, Georgios D. Kitsios^{3,5,7}
- 8
- 9 ¹ Internal Medicine Residency Program, UPMC, Pittsburgh, PA;
- 10 ² Karius Inc, Redwood City, CA;
- 11 ³Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA;
- 12 ⁴ Internal Medicine Residency Program, UPMC Mercy, Pittsburgh, PA;
- 13 ⁵ Acute Lung Injury Center for Excellence, Division of Pulmonary, Allergy and Critical Care Medicine, University
- 14 of Pittsburgh, Pittsburgh, PA;
- 15 ⁶ Veterans Affairs Pittsburgh Health System, Pittsburgh, PA;
- 16 ⁷Center for Medicine and the Microbiome, University of Pittsburgh, Pittsburgh, PA;
- 17 ⁸Computer Vision Group, Veytel LLC, Pittsburgh, PA;
- 18 ⁹University of Pittsburgh School of Medicine, Division of Infectious Diseases, Pittsburgh, PA.
- 19
- 20 Corresponding Author:
- 21 Georgios D. Kitsios, MD, PhD
- 22 Assistant Professor of Medicine
- 23 Division of Pulmonary, Allergy and Critical Care Medicine
- 24 University of Pittsburgh Medical Center
- 25 Address: UPMC Montefiore Hospital, NW628, 3459 Fifth Avenue, Pittsburgh, PA 15213
- 26 Email: kitsiosg@upmc.edu
- 27 **Summary of conflict-of-interest statements**: Drs. Duttagupta and Ahmed are employed by Karius, Inc. Dr.
- 28 Kitsios, Dr. Haidar have received research funding from Karius, Inc in 2018-2019. Dr. Mellors is a consultant to

- Gilead Sciences and owns shares or share options in Co-Crystal Pharmaceuticals, ID Connect, and Abound
- Bio, all unrelated to the current work. Dr. McVerry has received research funding from Bayer Pharmaceuticals,
- Inc. and consulting fees from Boehringer Ingelheim, both unrelated to this work. All other authors disclosed no
- conflict of interest.
- **Funding information**: Dr. Kitsios: University of Pittsburgh Clinical and Translational Science Institute, COVID-
- 19 Pilot Award; NIH (K23 HL139987; R03 HL162655). Dr. Bain: Career Development award number IK2
- BX004886 from the U.S. Department of Veterans Affairs Biomedical Laboratory R&D (BLRD) Service. Caitlin
- Schaefer: NIH (P01 HL114453).

- **Abstract**:
- Background: Secondary infection (SI) diagnosis in COVID-19 is challenging, due to overlapping clinical
- presentations, practical limitations in obtaining samples from the lower respiratory tract (LRT), and low
- sensitivity of microbiologic cultures.
- Research Question: Can metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA-Seq) help
- diagnose SIs complicating COVID-19?
- Study Design and Methods: We enrolled 42 inpatients with COVID-19 classified as microbiologically-confirmed
- SI (Micro-SI, n=8), clinically-diagnosed SI (Clinical-SI, n=13, i.e. empiric antimicrobials), or no clinical suspicion
- for SI (No-Suspected-SI, n=21) at time of enrollment. From baseline and follow-up plasma samples (days 5
- and 10 post-enrollment), we quantified mcfDNA for all detected microbes by mcfDNA sequencing and
- measured nine host-response biomarkers. From LRT samples among intubated subjects, we quantified
- bacterial burden with 16S rRNA gene quantitative PCR.
- Results: We performed mcfDNA-Seq in 82 plasma samples. Sequencing was successful in 60/82 (73.2%)
- samples, which had significantly lower levels of human cfDNA than failed samples (p<0.0001). McfDNA
- detection was significantly higher in Micro-SI (15/16 [94%]) compared to Clinical-SI samples (8/14 [57%],
- p=0.03), and unexpectedly common in No-Suspected-SI samples (25/30 [83%]), similar to detection rate in
- Micro-SI. We detected culture-concordant mcfDNA species in 13/16 Micro-SI samples (81%) and mcfDNA
- levels tracked with SI outcome (resolution or persistence) under antibiotic therapy. McfDNA levels correlated
- significantly with LRT bacterial burden (r=0.74, p=0.02) as well as plasma biomarkers of host response (white
- blood cell count, IL-6, IL-8, and SPD, all p<0.05). Baseline mcfDNA levels were predictive of worse 90-day
- 57 survival (hazard ratio 1.30 [1.02-1.64] for each log_{10} mcfDNA, p=0.03).
- Interpretation: High circulating levels of mcfDNA in a substantial proportion of patients with COVID-19 without
- clinical suspicion for SI suggest that SIs may often remain undiagnosed. McfDNA-Seq, when clinically
- available, can offer a non-invasive diagnostic tool for pathogen identification, with prognostic value on host
- inflammatory response and clinical outcomes.
- **Key Words:** COVID-19, microbial cell-free DNA sequencing, secondary infection, pneumonia, acute
- respiratory failure

Introduction:

 Secondary bacterial or fungal infections complicate the course of up to 50% of hospitalized patients 66 with COVID-19 and contribute to worse clinical outcomes.¹⁻³ Diagnosis of secondary infections (SI) has presented clinicians with major challenges during the pandemic. Readily available indicators of clinical infection such as fever, leukocytosis or consolidations on chest imaging cannot distinguish isolated SARS-CoV-2 69 infection from a secondary pneumonia by super-infecting organisms. $4,5$ Blood cultures are obtained routinely when a SI is suspected in COVID-19, but their diagnostic yield is low, especially in the case of secondary 71 pneumonias, when direct lower respiratory tract (LRT) sampling is recommended.⁶ LRT sampling for microbiologic studies can be challenging, such as in severely hypoxemic patients on non-invasive respiratory support, and can have low diagnostic sensitivity, due to antecedent antibiotics or slow/fastidious organism 74 growth, as in the case of fungal pathogens.⁷

 The challenges of SI diagnostic work-up and variable clinical practices have hindered acquisition of accurate SI incidence estimates in severely ill patients with COVID-19. With the prevailing diagnostic uncertainty, empiric antibiotics have been prescribed in 75-85% of hospitalized patients, often initiated due to clinical deterioration and then empirically continued, even in the absence of diagnostic evidence supporting an 79 SI.^{8,9} Overcoming the diagnostic challenges of SI with reliable, sensitive and non-invasive techniques could optimize diagnostic yield, enabling antibiotic targeting and stewardship.⁴

 Metagenomic sequencing of plasma microbial cell-free DNA (mcfDNA) can offer a non-invasive, sensitive diagnostic tool for SIs caused by DNA pathogens. Plasma metagenomics in sepsis provides rapid 83 and actionable results, with 95% concordance with blood-cultured organisms, facilitating adjustments of 84 empiric antimicrobials to targeted therapy.¹⁰ We have previously provided proof-of-concept evidence that patients with COVID-19 with high levels of circulating mcfDNA of common respiratory pathogens were at risk of 86 worse clinical outcome.¹¹ Although the ability to comprehensively assess for SI-causal pathogens with non- invasive blood samples is appealing, feasibility and clinical validity data for mcfDNA sequencing in COVID-19 are needed. In this study, we report the analyses of a cohort of 42 hospitalized patients with severe COVID-19 who were comprehensively screened for SI pathogens with serial plasma mcfDNA sequencing.

-
- **Methods:**

92 Clinical cohort enrollment and COVID-19 diagnosis: From April 2020 through September 2020, we conducted an observational, prospective cohort study of hospitalized patients with acute hypoxemic respiratory 94 failure and confirmed severe COVID-19 pneumonia as previously described.^{12,13} The University of Pittsburgh Institutional Review Board (IRB) approved the protocols and we obtained written or electronic informed consent by all participants or their surrogates in accordance with the Declaration of Helsinki. We diagnosed COVID-19 based on institutional clinical criteria (clinical symptoms, hypoxemia and abnormal chest radiographic findings) with confirmatory molecular testing (positive SARS-CoV-2 nasopharyngeal quantitative 99 polymerase chain reaction [qPCR]).

 Biospecimen collection and experiments: We collected blood samples in EDTA tubes on enrollment (baseline - day 1) for centrifugation, separation and storage of plasma and additional blood constituents until conduct of experiments. We also collected repeat blood samples on days 5 and 10 post-enrollment from critically ill patients who remained hospitalized in the intensive care unit (ICU). We collected endotracheal aspirates (ETA) from mechanically-ventilated patients concurrently with blood sample acquisition.

 We conducted plasma microbial cell-free DNA metagenomic sequencing (mcfDNA-Seq) with the Karius 106 Test[®] [Karius Inc., Redwood City, CA] and classified the derived metagenomic sequences as human (hcfDNA) vs. microbial (mcfDNA). Based on minimum sequencing coverage metric required for quality control, we classified sequencing runs as "Pass", "Qualitatively Pass" or "Failed". All microbes were reported at species level and included a quantitative measure of abundance expressed as DNA molecules per microliter (MPMs), with the exception of the "Qualitative Pass" calls where the reported organism could not be quantified. We classified microbes identified by mcfDNA-Seq into recognized respiratory pathogens vs. microbes of unclear 112 clinical importance.¹⁴ For contextualization, we compared mcfDNA levels among subjects with COVID-19 with 113 our previously published dataset of mechanically ventilated patients with and without pneumonia.¹⁴

 To profile the host response, we measured plasma levels of nine prognostic biomarkers (eight interleukin [IL]-6, IL-8, pentraxin-3, procalcitonin, receptor for advanced glycation end products [RAGE], angiopoietin-2 (Ang-2), suppression of tumorigenicity [ST]-2, and tumor necrosis factor receptor [TNFR]-1 with Luminex, and surfactant Protein D [SPD] with ELISA; R&D Systems, Minnesota). We measured plasma SARS-118 CoV-2 viral levels (vRNA) following RNA extraction and qPCR amplification with a sensitive in-house method.¹⁵ From available ETA samples, we separately extracted genomic DNA and RNA and performed bacterial 16S

rRNA gene and SARS-CoV-2 RNA qPCR for assessment of bacterial and viral load in the LRT,

121 respectively.^{5,16}

Diagnosis and classification of secondary infections:

 We reviewed all available clinical, microbiologic and antimicrobial treatment data around the timing of baseline samples (+/- 3 days) for patients with COVID-19 to ascertain the presence/absence or clinical suspicion for SI. We classified subjects in three groups, assessed by two reviewers:

- a. Microbiologically-Confirmed Secondary Infection (**Micro-SI**), when typical pathogenic microbes were 127 isolated on clinical biospecimen cultures (blood, LRT, urine or tissue) and the subject was receiving antimicrobials for the documented infection.
- b. Clinically-Diagnosed Secondary Infections (**Clinical-SI**), when empiric antimicrobials were administered without microbiologic SI confirmation.
- c. "No Clinical Suspicion for SI" (**No-Suspected-SI**), when microbiologic workup for SI was negative or not performed, and no empiric antimicrobials were prescribed.

 We repeated classifications into the Micro-SI, Clinical-SI and No-Suspected-SI categories at the timing of follow-up samples (days 5 and 10 post-enrollment) from updated clinical and microbiologic data, when available. We quantified radiographic edema of baseline chest x-rays with the Radiographic Assessment of Lung Edema (RALE) score with the use of the *PulmAnnotator* software. 17,18

Statistical analysis:

139 For "Pass" samples with zero microbial calls, we assigned a microbial MPM of "1" to allow for log₁₀-140 transformations, and utilized log₁₀-transformed values of plasma biomarkers and mcfDNA levels for analyses due to non-normal data. We compared clinical variables, biomarker and cfDNA levels between different categories (i.e. sequencing run success, SI clinical groups) and the historical non-COVID-19 cohort using non-143 parametric tests, Wilcoxon signed-rank and Fischer's exact tests. We examined for correlations between biomarkers and cfDNA levels with the Pearson's method, adjusted for multiple comparisons with the Benjamini-Hochberg method. We analyzed the impact of baseline mcfDNA levels on 90-day survival by Kaplan-Meier curves stratified by total mcfDNA tertiles and by constructing Cox proportional age-adjusted hazards models. We performed all analyses with the R software (R version 3.5.1).

Results:

Clinical cohort characteristics:

 We included 42 patients (median age 65.1 years, 62% men), who contributed a total of 82 plasma samples for cfDNA sequencing (median of 2 samples per subject). From available baseline data, we classified subjects as Micro-SI (n=8), Clinical-SI (n=13) and No-Suspected-SI (n=21) (Table 1). We found lower rates of 154 invasive mechanical ventilation ($p = 0.05$) and lower total white blood cell count ($p=0.04$) in Clinical-SI patients and no other significant clinical variable differences between SI groups. Plasma vRNA was notably lower in Micro-SI (p≤0.05). In biomarker comparisons, we found significant between-group differences in IL-8 and Ang-2 levels (lower in Clinical-SI).

Outputs of plasma metagenomic sequencing runs:

 Based on the sequencing run success criteria of the 82 samples, we classified 52 (63%) as "Pass" (successful), eight (10%) as "Qualitative Pass" and 22 samples (27%) as "Fail". "Pass" samples had significantly lower levels of hcfDNA compared to "Qualitative Pass", or "Fail" samples (p<0.0001, e-Figure 1). We also found that a successful sequencing run ("Pass") on a Day 1 sample for a given subject was significantly associated with a "Pass" run on a Day 5 sample (Fisher's odds ratio 11.9, 95% confidence interval-CI [1.00-703.8], p=0.04). From "Qualitative Pass" samples, we utilized only qualitative information about identified microbial species, whereas we utilized quantitative mcfDNA data (expressed as MPMs) from "Pass" samples only.

Plasma metagenomics results by SI category:

 Among the 53 "Pass" samples across all time-points, Micro-SI diagnosis had more samples positive for mcfDNA (i.e. DNA reads from at least one microbial species reported, 15/16 [94%] samples) compared to Clinical-SI (8/14 [57%], p=0.03). Unexpectedly, a high proportion of No-Suspected-SI samples were positive for mcfDNA (25/30 [83%]), similar to Micro-SI samples. All eight "Qualitative Pass" samples, one Clinical-SI and seven No-Suspected-SI, were positive for mcfDNA, with 3/8 samples reporting ≥2 microbial species.

 Among baseline "Pass" samples (n = 25), 18 (72%) were positive for mcfDNA, with a median (interquartile range – IQR) of 812.9 (151.3-2435.5) MPMs per sample, 59.1% of which corresponded to typical pathogenic organisms. Stratified by SI categories, 4/5 (80.0%) Micro-SI, 3/8 (37.5%) Clinical-SI and 11/12 (91.6%) No-Suspected-SI samples were positive for mcfDNA, with a statistically significant higher proportion of 179 positive samples in No-Suspected-SI compared to Clinical-SI samples (Fisher's p=0.01). We found no significant differences in hcfDNA, total mcfDNA and pathogen mcfDNA MPMs between SI groups (Figure 1A- C), although Micro-SI samples had numerically higher total and pathogen mcfDNA MPM levels (Table 1). Among baseline "Pass" samples in Micro-SI subjects, plasma metagenomics reported mcfDNA from the culprit organisms identified by cultures in 3/5 (60.0%) cases (*E.coli* in subject 4, *Pseudomonas aeruginosa* in subject 3 and *Proteus mirabilis* in subject 6) (e-Figure 2, eTable 2). The two discordant Micro-SI samples involved two probable ventilator-associated pneumonia (VAP) cases: subject 1 with negative mcfDNA-Seq when LRT cultures taken three days prior to plasma sampling showed rare *E.coli* growth, and case subject 2 with light Methicillin-sensitive *S. aureus* growth in LRT cultures taken two days prior to plasma sampling was deemed as culprit, but mcfDNA-Seq reported *E. faecalis* and *E.coli* mcfDNA. When considering all available Micro-SI samples (five baseline and 11 follow-up samples), mcfDNA-Seq results were concordant with cultures in 13/16 (81.3%) of comparisons.

 Baseline samples from Clinical-SI subjects contained mcfDNA in 37.5 % of cases (3/8). Case 11 had high mcfDNA levels for plausible pathogens (*K. pneumoniae* and *P. aeruginosa*; Figure 1C, e-Figure 2, and eTable 2), which had not been detected by blood cultures (no LRT specimen cultures available). For the other two Clinical-SI subjects (15 and 21), reported mcfDNA belonged mostly to Human Herperviruses, which could 195 represent viral re-activation in context of critical illness.¹⁹

 Among No-Suspected-SI patients at baseline, 11/12 (91.6%) samples were positive for mcfDNA, with five samples showing >100 pathogen mcfDNA MPMs in the range of Micro-SI subjects (annotated species in Figure 1C, e-Figure 2). The remaining six subjects with mcfDNA revealed organisms of unclear clinical significance: Herpesvirus DNA in four subjects (27, 28, 38 and 42), and gram-positive bacteria often considered as skin contaminants in blood cultures (*Lactobacillus gasseri* and *S. epidermidis*) in three subjects (38, 41 and 42). Notably, 3/4 (75%) of the baseline "Qualitative Pass" samples for No-Suspected-SI subjects

202 (25, 30, 36) were also positive for pathogen mcfDNA, even though the absolute burden of mcfDNA MPMs

203 could not be reliably estimated.

205 Comparison of circulating cfDNA burden in COVID-19 vs. historic non-COVID samples:

Comparing against published data from our group for mechanically ventilated patients with

207 microbiologically confirmed pneumonia (n=26), clinically diagnosed pneumonia (n=41) and uninfected controls

(n=16, intubated for airway protection or due to cardiogenic pulmonary edema), we found markedly higher

levels of hcfDNA in subjects with COVID-19 compared to all non-COVID patient groups (e-Figure 3A, p<0.005

210 for all comparisons). Patients without COVID with microbiologically confirmed pneumonia had higher mcfDNA

211 levels compared to No-Suspected-SI in patients with COVID-19, who in turn had markedly higher mcfDNA

levels compared to uninfected controls (e-Figure 3B-C, all p<0.05).

Trajectories of plasma cfDNA levels in subjects with COVID-19:

 We updated SI classifications at the time of the follow-up sample acquisition and found that few subjects transitioned into a different SI diagnostic category (4/26 [15%] and 4/16 [25%] for days 5 and 10, respectively, e-Figure 4, 5). Micro-SI subjects had significantly higher total and pathogen mcfDNA levels compared to No-Suspected-SI subjects at post-enrollment day 5 (p<0.05, e-Figure 5).

 We examined subject-level trajectories in four cases with persistent culture-proven SI or persistent 220 pathogen mcfDNA detection on available longitudinal samples (Figure 2). Subject 3 was diagnosed with resistant *Pseudomonas aeruginosa* VAP with clinical and microbiologic relapse, demonstrating persistently elevated *Pseudomonas aeruginosa* mcfDNA for >30 days on repeated sampling (Figure 2). For subject 4 223 McfDNA-Seg demonstrated a transition in detected bacterial species in follow-up samples corresponding to two different VAP episodes (by *E. coli* and *Pseudomonas aeruginosa* respectively). Subject 6 had unexplained, persistent *Proteus mirabilis* mcfDNA detection following treatment of a urinary tract infection, but was found to have a late parotid gland abscess that was drained and cultures grew *Proteus mirabilis*. Last, for subject 26 diagnosed as No-Suspected-SI (i.e. no empiric antimicrobials) who died on day 6 with multi-organ failure attributed to isolated SARS-CoV-2 infection, we found high pathogen mcfDNA levels, including *Klebsiella pneumoniae*, raising concern for the possibility of an undetected and undertreated SI.

McfDNA is associated with plasma host-response biomarkers and LRT bacterial burden:

 We next examined the relationship between mcfDNA-Seq results and clinical/laboratory parameters of COVID-19 severity. We found no significant correlation between mcfDNA and SARS-CoV-2 viral load (plasma 234 and ETA vRNA), radiographic severity (quantified by RALE scores) or clinical severity by WHO ordinal scale. However, there was a weak, significant correlation between hcfDNA and RALE scores (r=0.33, p=0.03). We then examined for correlations between cfDNA levels and host-response biomarkers measured in 237 plasma. Total and pathogen mcfDNA levels were significantly correlated with IL-6, IL-8 and SPD levels, whereas hcfDNA levels were significantly correlated with IL-6, IL-8, pentraxin-3 and procalcitonin levels following adjustment for multiple comparisons (Figure 3). Pathogen mcfDNA levels were significantly correlated 240 with 16S rRNA gene copies by qPCR in ETA specimens, a surrogate of LRT bacterial load (r=0.92, p=0.0004). Baseline mcfDNA levels are predictive of 90-day survival: Baseline hcfDNA and total mcfDNA levels were not significantly associated with cumulative mortality at 90 days from ICU admission (Figure 4A-B). However, baseline total mcfDNA levels were significantly associated with worse 90-day survival in a Cox proportional hazards model adjusted for age (hazard ratio for log₁₀-transformed mcfDNA 1.30, [1.02-1.64], p=0.03). Stratified by baseline total mcfDNA tertiles (high>1499, middle 344-1499, low<344 MPMs), subjects in the high mcfDNA tertile had worse 90-day survival by Kaplan-248 Meier curve analysis compared to subjects in other tertiles (global log-rank p=0.02), whereas hcfDNA tertiles

Discussion:

between survivors and non-survivors (e-Figure 5A, B).

 In this exploratory study, we systematically evaluated 42 COVID-19 inpatients with culture-independent mcfDNA-Seq. We found no significant differences in mcfDNA levels by SI clinical categories at baseline,

were not predictive of 90-day survival (Figure 4C-D). In contrast to the significant prognostic information of

baseline total mcfDNA levels, there were no 90-day survival differences between the clinical classification SI

groups (log-rank p=0.62 for Micro-SI, Clinical-SI and No-Suspected-SI, data not shown). Stratified by 90-day

survival, we found no significant differences in the longitudinal trajectories of total mcfDNA and hcfDNA levels

258 although culture-confirmed cases of SI (Micro-SI) had higher mcfDNA levels on follow-up samples. The 259 mcfDNA species corresponded to clinically isolated pathogens in 81% of Micro-SI samples, and indicated 260 potentially missed, super-infecting pathogens in up to 41% of subjects for whom there was no clinical suspicion 261 for SI (No-Suspected-SI). Our molecular analyses revealed significant correlations of circulating mcfDNA levels 262 with LRT bacterial burden, suggestive of plausible secondary pneumonias, as well as with plasma host-263 response biomarkers. Subjects with the highest tertile of mcfDNA burden had significantly lower 90-day 264 survival independent of SI group. Longitudinal assessments revealed that mcfDNA levels can persist in SI 265 without adequate source control such as the patient with parotitis or potentially with antibiotic resistant 266 pathogens such as the patient with resistant *Pseudomonas* VAP. Our results were also notable for an 267 unexpectedly high rate of failed mcfDNA-Seq runs due to high burden of circulating hcfDNA, which was much 268 higher than historic cases of non-COVID-19 pneumonia, perhaps due to significant human tissue damage in 269 severely ill patients with COVID-19, including patients supported by extra-corporeal membrane oxygenation. 270 The higher likelihood of subsequent failed samples after initial failed samples suggests subject-specific 271 influences on sequencing run outputs and results.

272 Our study highlights the challenge of clinically distinguishing cases with isolated SARS-CoV-2 infection 273 from those complicated by SIs. The results of host-response biomarker analyses and mcfDNA-Seq did not 274 match the clinical SI diagnoses and clinically-directed microbiologic work-up. For example, procalcitonin levels 275 are often used as diagnostic biomarkers for bacterial infections, but have unclear diagnostic value for SIs in 276 COVID-19.^{20,21} We found similar procalcitonin levels among clinical SI groups, and importantly no significant 277 association with mcfDNA levels. The clinical validity of mcfDNA sequencing was further supported by the 278 significant correlations with LRT bacterial burden and systemic host-response biomarkers, as well as by the 279 predictive value on 90-day survival. Our study suggests that noninvasive mcfDNA sequencing may offer 280 insights into the presence of an SI and its impact on outcome.

281 Circulating mcfDNA was significantly associated with host immune response in COVID-19. McfDNA 282 species may reflect SI-causal pathogens (regardless of their viability in the bloodstream), but may also signify 283 lung barrier disruption in patients with acute lung injury from COVID-19, or even gut barrier disruption in 284 patients with circulatory shock and hypoperfusion.¹⁴ Thus, positive mcfDNA calls should not be directly 285 interpreted as evidence of superinfecting pathogens, but interpreted within the context of a critical illness with

 colonized mucosal surfaces by microbiota and impaired barrier function. The significant correlation between 287 hcfDNA levels and RALE scores suggests that lung injury may account, at least in part, for the systemic levels of circulating hfcDNA. The significant correlations of mcfDNA with IL-6 and IL-8 levels highlighted the potential importance of mcfDNA in the inflammatory cascade of COVID-19, since mcfDNA can be recognized by Toll-290 like receptors and propagate systemic inflammatory responses, independent of the effects of SARS-CoV-2 on 291 innate immunity.²² Additionally, the case of Herpesvirus DNA identification highlighted the prevalence of viral re-activation in critical illness. Thus, any positive mcfDNA signal requires careful interpretation, as it may represent superinfecting bacterial or fungal VAP pathogens, translocating commensal microbes, sample collection skin/environmental contaminants or re-activated viral organisms.

295 Our study has several limitations. The sample size of 42 subjects limits the statistical power for some of 296 the analyses, yet it is to our knowledge the largest study to utilize plasma metagenomics in patients with COVID-19, and we found significant associations with host inflammation and outcomes, consistent with our hypotheses. Clinical samples for microbiologic workup were collected at the discretion of the treating clinicians, 299 and thus some of the mcfDNA-culture comparisons are limited. Nonetheless, our clinical dataset is representative of standard of care at a tertiary academic center. We systematically examined all patients for molecular evidence of possible SI using systematic evaluation with mcfDNA testing, regardless of clinician impressions. It is possible that for certain No-Suspected-SI subjects, the mcfDNA reported may not represent an active infection. Careful review of the mcfDNA-Seq output and integration with available evidence on organismal pathogenicity can help further inform interpretation of pathogen mcfDNA. Nonetheless, circulating mcfDNA carries prognostic information underlined by the significant associations with systemic inflammation 306 and survival.¹¹ Our study was limited by an unexpected amount of failed mcfDNA-Seq analyses due to high amounts of interfering hcfDNA, but this finding provided important insight into the high degree of human cellular damage in COVID-19.

 Our study advances understanding of the pathobiologic and diagnostic importance of circulating mcfDNA in COVID-19 and demonstrates limitations in clinical assessment of SIs. McfDNA correlated with biomarkers of host immune response and LRT microbial burden. Additional characterization of host 312 inflammatory response components and triggers in COVID-19 is essential in the era of immunomodulatory therapeutics. The noninvasive modality of quantifying mcfDNA load and accurately identifying microbial

- species may offer a sensitive tool for SI detection, as well as further advance our understanding of the role of
- translocating microbiota in critical illness. McfDNA sequencing may be particularly helpful in spontaneously
- breathing patients on high flow nasal cannula or non-invasive mechanical ventilation, for whom access to LRT
- specimens is challenging. Further prospective investigation for treatment guidance is necessary to
- systematically evaluate the incidence of molecular evidence for SI and examine the impact of non-invasive
- screening on patient outcomes.

References

study. *Intensive Care Med.* 2021;47(2):188-198.

- 3. Maes M, Higginson E, Pereira-Dias J, et al. Ventilator-associated pneumonia in critically ill patients with COVID-19. *Crit Care.* 2021;25(1):25.
- 4. Pickens CO, Gao CA, Cuttica MJ, et al. Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. *Am J Respir Crit Care Med.* 2021;204(8):921-932.
- 5. Kitsios GD, Morris A. Seek and Ye Shall Find: COVID-19 and Bacterial Superinfection. *Am J Respir Crit Care Med.* 2021;204(8):875-877.
- 6. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect.* 2020;26(10):1395-1399.
- 335 7. Investigators NC. Bronchoscopy on intubated patients with COVID-19 is associated with low infectious risk to operators. *Annals of the American Thoracic Society.* 2021;18(7):1243-1246.
- 8. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. *Clin Microbiol Infect.* 2021;27(4):520-531.
- 9. Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. *The Lancet Microbe.* 2021;2(8):e354-e365.
- 10. Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. *Nat Microbiol.* 2019;4(4):663-674.
- 11. Kitsios GD, Bain W, Al-Yousif N, et al. Plasma microbial cell-free DNA load is associated with mortality in patients with COVID-19. *Respir Res.* 2021;22(1):24.
- 12. Drohan CM, Nouraie SM, Bain W, et al. Biomarker-Based Classification of Patients With Acute Respiratory Failure Into Inflammatory Subphenotypes: A Single-Center Exploratory Study. *Crit Care Explor.* 2021;3(8):e0518.
- 13. Bain W, Yang H, Shah FA, et al. COVID-19 versus Non-COVID-19 Acute Respiratory Distress Syndrome: Comparison of Demographics, Physiologic Parameters, Inflammatory Biomarkers, and Clinical Outcomes. *Ann Am Thorac Soc.* 2021;18(7):1202-1210.
- 14. Yang H, Haidar G, Al-Yousif NS, et al. Circulating microbial cell-free DNA is associated with inflammatory host-responses in severe pneumonia. *Thorax.* 2021;76(12):1231-1235.
- 15. Jacobs JL, Bain W, Naqvi A, et al. SARS-CoV-2 Viremia is Associated with COVID-19 Severity and Predicts Clinical Outcomes. *Clin Infect Dis.* 2021.
- 16. Jacobs J, Naqvi A, Shah F, et al. Plasma SARS-CoV-2 RNA levels as a biomarker of lower respiratory tract SARS-CoV-2 infection in critically ill patients with COVID-19. *Journal of Infectious Diseases.* 2022;In press.
- 17. Kotok D, Yang L, Evankovich JW, et al. The evolution of radiographic edema in ARDS and its association with clinical outcomes: A prospective cohort study in adult patients. *J Crit Care.* 2020;56:222-228.
- 18. Al-Yousif N, Komanduri S, Qurashi H, et al. Radiographic Lung Edema in Hospitalized Patients with COVID-19 Is Associated with Disease Severity and Clinical Outcomes. *B104. COVID ACROSS THE CARE CONTINUUM*: American Thoracic Society; 2022:A3554-A3554.
- 19. Meyer A, Buetti N, Houhou-Fidouh N, et al. HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. *Crit Care.* 2021;25(1):417.

- 20. Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. *Ann Clin Biochem.* 2021;58(5):520-527.
- 21. Atallah NJ, Warren HM, Roberts MB, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study. *PLoS One.* 2022;17(1):e0262342.
- 22. Savva A, Roger T. Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. *Frontiers in immunology.* 2013;4:387.

373 **TABLE 1: Cohort characteristics by COVID-19 and SI category**

³⁷⁴ *COVID-19 diagnosis made by positive nasopharyngeal (NP) qPCR test for SARS-CoV-2 in 42/43 subjects, and for one subject with negative NP

375 qPCR test by positive anti-spike protein antibodies (patient enrolled in April 2020, prior to initiation of vaccination programs). P-values significant

376 below threshold of 0.05 are shown in bold. Abbreviations: Microbiologically-Diagnosed Secondary Infection (Micro-SI); Clinically-Diagnosed

377 Secondary Infections (Clinical-SI); No Clinical Suspicion for SI (No-Suspected-SI); chronic obstructive pulmonary disease (COPD); extracorporeal

378 membrane oxygenation (ECMO); Radiographic Assessment of Lung Edema score (RALE score); receptor for advanced glycation end products

379 (RAGE); suppression of tumorigenicity (ST-2); tumour necrosis factor receptor (TNFR-1); Surfactant Protein D (SPD); molecules per microliter

380 (MPMs).

Figure 1:

significant differences in human (A) or microbial cell-free DNA levels (B-C). Subjects classified as

- Microbiologically-Confirmed Secondary Infection (Micro-SI) had numerically higher but statistically non-
- significant different levels of total and pathogen microbial cell-free DNA (mcfDNA) compared to subjects
- classified as Clinically-Diagnosed Secondary Infections (Clinical-SI) or those with no Clinical Suspicion for SI
- (No-Suspected-SI). Pairwise comparisons were conducted with Wilcoxon test. In panel C, the most abundant
- microbial species in each of the positive samples for pathogen mcfDNA are shown.

Figure 2:

393 Figure 2: Comparison of plasma mcfDNA sequencing with microbiologic/clinical diagnoses across the timeline
394 of four subjects with serial sampling. Species-specific microbial MPMs (y-axis) are shown across sequential of four subjects with serial sampling. Species-specific microbial MPMs (y-axis) are shown across sequential sampling days from enrollment, (x-axis). Petri dish graphics along the x-axis denote the timing and results of 396 clinically obtained microbiological testing. Subject 3 (A) was an immunocompetent patient with a persistent
397 culture-confirmed *Pseudomonas* VAP that persisted through the antimicrobials, with timing and therapy not culture-confirmed *Pseudomonas* VAP that persisted through the antimicrobials, with timing and therapy noted 398 above. Subject 3 had persistently elevated *Pseudomonas* mcfDNA levels throughout the extended infection
399 course, which ultimately correlated with clinical improvement (A). Subject 4 (B) had sequential VAPs with course, which ultimately correlated with clinical improvement (A). Subject 4 (B) had sequential VAPs with changing pathogens detected on invasive respiratory cultures, *E. coli* followed by *Pseudomonas*, which was concordantly reported on noninvasive mcfDNA sampling. Subject 6 (C) was a patient with diabetes who was initially found to have a resistant *Proteus* urinary infection, and a subsequent persistent septic clinical picture, later found to have a polymicrobial, including *Proteus*, parotid gland abscess. *Proteus* mcfDNA levels remained elevated in Subject 6 during initial antimicrobial therapy for urinary infection, suggesting the persistent source of infection. Subject 26 (D) was clinically determined No-Suspicion-for-SI, but had a deteriorating clinical course, without cultures obtained for 5 days or empiric antimicrobials, and ultimately died of shock and multisystem organ failure. Noninvasive testing revealed persistent levels of *Klebsiella pneumonia* mcfDNA levels, which suggests an undiagnosed SI may have contributed to the clinical course. Figure 3:

410

411 Figure 3: Plasma microbial cell-free DNA levels were significantly correlated with lower respiratory tract 412 bacterial load and plasma host response biomarkers. Correlogram demonstrating comparisons of host nine 413 response biomarkers (green dashed box), number of 16S rRNA gene copies by qPCR in Endotracheal 414 Aspirates (ETA, surrogate for lower respiratory tract bacterial load), number of SARS-COV-2 RNA copies in 415 ETA and plasma samples by qPCR, and mcfDNA-Seq output (hcfDNA, total mcfDNA and pathogen mcfDNA – 416 purple dashed box). Significant correlations with the Pearson's method and following adjustment for multiple 417 comparisons by the Benjamini-Hochberg method are shown, with direction and strength of correlation depicted 418 by the color scale on the right panel.

421

422 Figure 4: Highest microbial cell-free DNA levels at baseline were significantly associated with worse 90-day 423 survival. 90-day non-survivors had numerically higher (but statistically non-significant) plasma hcfDNA (A) and 424 mcfDNA (C) levels. HcfDNA levels were not significantly associated with 90-day survival by Kaplan-Meier 425 analysis (B). Patients with the highest tertile of mcfDNA (>1499 Molecules per Microliter) had significantly 426 worse survival compared to patients in the other two mcfDNA tertiles (D). In a Cox proportional hazards model 427 adjusted for age, mcfDNA levels were significantly associated with increased hazards of death (D, adjusted 428 hazard ratio for log_{10} -transformed mcfDNA 1.30, 95% confidence interval 1.02-1.64, p=0.03).

430 **SUPPLEMENT:**

431 **e-Table 1: Baseline characteristics by sequencing run success.**

- 434 (COPD); extracorporeal membrane oxygenation (ECMO); Radiographic Assessment of Lung Edema score (RALE score); receptor for advanced
- 435 glycation end products (RAGE); suppression of tumorigenicity (ST-2); tumour necrosis factor receptor (TNFR-1); Surfactant Protein D (SPD);
- 436 molecules per microliter (MPMs).

 e-Figure 1: Successful plasma metagenomic sequencing runs had significantly lower levels of human cell-free DNA compared to unsuccessful runs. We classified the derived metagenomic sequences as human (hcfDNA) vs. microbial (mcfDNA), expressed as molecules per microliter (MPMs). Based on meeting minimum 442 sequencing coverage metric required for quality control, we classified sequencing runs as successful ("Pass"), "Qualitatively Pass" or "Failed". Baseline "Pass" samples had significantly lower hcfDNA compared to "Qualitatively Pass" or "Failed" samples (Wilcoxon test pairs p<0.001, panel A). We also found that among subjects with both Day 1 and Day 5 samples, those samples that failed on both time points per subject (i.e. "0" sequencing success in panel B) had significantly higher hcfDNA levels compared to "Pass" samples on both days (Wilcoxon p-value <0.001).

-
-
-
-

e-Figure 2:

McfDNA results by Subject

e-Figure 2: Significantly higher proportion of positive samples with mcfDNA species calls in No-Suspected-SI

compared to Clinical-SI samples. We display samples grouped by SI classification and sample identifier,

showing the species and respective MPMs called by mcfDNA-Seq. Standardized bars indicate failed samples,

457 samples with no species called, and those with qualitative pass, yielding species each denoted with

standardized bar. Infrequently called species were combined for visual simplicity.

e-Figure 3:

461

462 e-Figure 3: Subjects with COVID-19 have much higher levels of human cell-free DNA compared to non-COVID 463 subjects with and without pneumonia. To contextualize the circulating cfDNA load in our COVID-19 cohort, we 464 compared hcfDNA, total mcfDNA and pathogen mcfDNA MPMs between the COVID-19 SI categories against

- 465 available published data from our group for mechanically ventilated patients with microbiologically-confirmed
- pneumonia (n=26, MCP), clinically-diagnosed pneumonia (n=41, CDP) and uninfected controls (n=16,
- intubated for airway protection or due to cardiogenic pulmonary edema). We found markedly higher levels of
- hcfDNA in subjects with COVID-19 compared to all non-COVID patient groups (p-values shown for the No-
- Suspected-SI only for parsimony). Non-COVID patients with microbiologically-confirmed pneumonia had higher
- mcfDNA levels compared to patients with COVID-19 with No-Suspected-SI, who in turn had markedly higher
- mcfDNA levels compared to uninfected controls.
-
-

474 e-Figure 4:

475
476 e-Figure 4: Longitudinal subject, mcfDNA and human cfDNA changes across SI classification. This Sankey plot

477 shows the subjects who transitioned between SI categories throughout the study from days 1, to 5, and 10 (A).

- Height of bars represents number of subjects. Attrition occurred throughout the study leading to decreased
- height of day 5 and 10 nodes. HcfDNA was not significantly different among SI groups across the study period
- (B). Total mcfDNA was not significantly different among SI categories on enrollment (C). Micro-SI subjects had
- significantly higher total and pathogen mcfDNA versus No-Suspected-SI subjects at Day 5 (C, D).
-
- e-Figure 5:

e-Figure 5: Human and total mcfDNA trajectories among survivors and non-survivors. Trajectories of human

cfDNA and total mcfDNA were not significantly different across the study period in survivors and non-survivors

- (A, B).
-
-
-
-

492 e-Table 2: Subject cfDNA and culture results

493 Abbreviations: Not detected (ND); no growth (NG); normal respiratory flora (NRF); gram stain (GS); culture (Cx); gram negative rods (GNRs); gram

494 positive cocci in chains (GPCCH); gram positive cocci in pairs (GPCP); T2 Candida fungal test (T2).

495

496 e-Table 3: Microbial species classifications

